FIELD: pharmacology.
SUBSTANCE: invention relates to new arylcycloalkylamines of the general formula
. In the general formula (I), R1, R2 are H, linear or branched alkyl (C1-C4), linear or branched alkoxy (C1-C4), halogen; Y is -CH2-O-CH2-, - (CH2)n-, where n: 1-3; X is -CO-NH-(CH2)6-, -CO-(CH2)k-, -CH2-NH-(CH2)6-, -CH(CH3)-NH-(CH2)6-, -(CO)p-(CHR5)m, where p, m-: 0, 1, k: 2, 4-7, R5: H, linear alkyl C1-C5; R3, R4 are H, linear alkyl C1-C4, -CH2-C≡CH, -(CH2)2-O-(CH2)2-NH2, cyclopropyl, cyclopropylmethyl; 4-pyridinyl, an amino acid residue of a proteinogenic acyclic or aromatic α-amino acids, γ-aminobutyric acid, ε-aminocaproic acid, β-alanine; -CHR6-CH2-OR7, where R6: H or a linear or branched alkyl C1-C4, benzyl, R7: H, linear alkyl C1-C4, or R3, R4 together with the nitrogen to which they are attached, form a pyrrolidine, 2-(hydroxymethyl) pyrolidine, 4-aminopyridinium ring; G is (C1-C4) carboxylic acid, methanesulfonic acid or a mineral acid or water. As an acyclic or aromatic α-amino acid residue, they contain a proteinogenic α-amino acid residue. As (C1-C4) carboxylic acid, they contain at least one compound from the group consisting of acetic, fumaric, succinic, tartaric, malic and maleic acids. As a mineral acid, they contain at least one compound from the group consisting of hydrochloric, phosphoric, sulfuric acids. The preferred compounds are arylcycloalkylamine derivatives of the general formula 
, wherein Y: -CH2-O-CH2-, -(CH2)2-. The invention also relates to a pharmaceutical composition which can be a combination of arylcycloalkylamine derivatives and at least one substance from the group comprising levodopa, palmitoyle ethanolamide, N-(2-aminoethyl) palmitamide hydrochloride, rasagiline, risperidone, toloxaton, quetiapine, gamma-aminobutyric acid, sodium valproate, amitriptyline, clomepramine, fluoxetine, paroxetine, sertraline, phenylephrine, dexamethasone, prednisolone. The composition may be in the form of a tablet, capsule, pellet, powder for preparation of a solution for enteral administration, a solution for parenteral administration, a powder for preparation of a solution for parenteral administration.
EFFECT: neuroprotective, analgesic and antidepressant action.
11 cl, 13 tbl, 96 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRIALLILBORANE ADDUCTS WITH AMMONIA AND AMINES AS ALLYLATING REAGENTS | 2018 |
|
RU2678208C1 |
| 2-SUBSTITUTED-1,2,4,5-TETRAHYDRO-3H-PYRROLO[1,2-a][1,4]DIAZEPIN-3-ONES | 2011 |
|
RU2472795C1 |
| METHOD OF PRODUCING CREATINE AMIDES | 2015 |
|
RU2579120C1 |
| FUNCTIONALISED NANOPARTICLES, PREPARATION AND USE THEREOF | 2007 |
|
RU2437890C2 |
| SELECTIVE LIGANDS OF G-QUADRUPLEX STRUCTURES OF NUCLEIC ACIDS | 2015 |
|
RU2588131C1 |
| 4-SUBSTITUTED N-ARYL-1,8-NAPHTHALIMIDES, EXHIBITING PROPERTIES OF FLUORESCENT SENSORS ON METAL CATIONS AND METHODS FOR PRODUCTION THEREOF | 2012 |
|
RU2515195C1 |
| DERIVATIVES OF 1,4-DIOXIDE OF QUINOXALINE-2-CARBONITRILE INHIBITING TUMOUR CELLS GROWTH | 2016 |
|
RU2640304C1 |
| LUPANE DIPEPTIDE PROCESS | 2007 |
|
RU2357973C1 |
| PHOSPHINE-CONTAINING CALIXARENE LIGANDS, METHOD OF THEIR PRODUCTION AND USE | 2016 |
|
RU2646763C1 |
| N-(2-(2-(DIALKYLAMINO)ETHOXY)ETHYL)CARBOXAMIDES AND HYDROCHLORIDES THEREOF, HAVING ANTIARRHYTHMIC ACTIVITY, AND PHARMACEUTICAL COMPOSITIONS BASED THEREON | 2019 |
|
RU2712638C1 |
